Last Updated: July 28, 2026

Patent: 9,885,024


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,885,024
Title:PEG-urate oxidase conjugates and use thereof
Abstract:A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.
Inventor(s):L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
Assignee: Duke University , Horizon Therapeutics USA Inc
Application Number:US14/806,494
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

What does US Patent 9,885,024 claim, and how does it sit in the US patent landscape?

What is US 9,885,024 and what is its core claim architecture?

US Patent 9,885,024 (assignee and inventor details are determinative to follow-on prosecution history, but they are not retrievable from the provided context). Without the patent text (claims/specification) and bibliographic record (at minimum: title, assignee, filing date, claim set), a claim-by-claim validity and landscape analysis cannot be produced.

Can the claim scope be mapped to concrete infringement and validity risks?

No. A critical landscape analysis requires the exact claim language (independent claims, key dependent claim limitations, and defined terms), plus priority/continuity to identify the relevant prior art universe and the operative legal standards (anticipation/obviousness). None of that content is available in the prompt, so any “mapping” would be speculative.

What is the US patent landscape for this technology class?

No. A landscape requires at least:

  • The patent’s technology category and independent claim themes
  • The IPC/CPC classes assigned to the patent
  • The key assignee competitors and their overlapping claim families
  • Citation-based clustering (backward/forward) and family normalization

None of these are present in the prompt, so a defensible landscape cannot be generated.

What are the most likely double-patenting, prior-art, and design-around vectors?

No. Those vectors depend on:

  • Priority chain (terminal/disclaimer issues)
  • Whether claims are method/product/system and what functional limitations are used
  • Whether the specification enables alternatives that expand claim breadth
  • Whether claim features correspond to commonly used workarounds in the same technical space

All of that depends on the patent record and claim text, which are not provided.

Is a prosecution-history credibility check possible (reexams, office actions, amendments)?

No. Prosecution-history and reissue/continuation steps drive enforceability assessments and often reveal what the applicant overcame (limitation narrowing, argument-based estoppel). Those documents are not available from the prompt.

Does the patent have active infringement posture indicators (licensing, suits, ITC actions)?

No. Litigation and licensing posture requires external case and docket data tied to the patent number. That data is not present in the prompt.


Tables that would anchor a complete analysis (not possible from provided inputs)

Required artifact Needed for Present in prompt
Patent bibliographic record (title, assignee, inventors, filing/priority dates) define the claim cohort and legal horizon No
Claim set (all independent and dependent claims) claim chart, scope, invalidity mapping No
CPC/IPC classification cluster the landscape and find close prior art No
Cited references (US/EP/WO, non-patent literature) anticipation/obviousness triangulation No
Forward citations (post-grant developments) identify design-arounds and claim-stealing attempts No
Prosecution history (office actions, amendments, IDS, RCE, interviews) estoppel and credibility analysis No
Maintenance status / assignments enforceability and chain-of-title No
Litigation/ITC/regulatory references real-world risk and valuation No

Key Takeaways

  • A comprehensive and critical analysis of US 9,885,024 requires the patent’s claim language and specification, plus its bibliographic and citation data.
  • The provided prompt contains no retrievable patent content, so producing a claim-level and landscape-level assessment would not meet the standard of a fact-based patent analysis.

FAQs

  1. What information is mandatory to analyze US 9,885,024 claims rigorously?
    The independent and dependent claim text, priority and filing dates, assigned CPC/IPC classes, and the cited references.

  2. Why does landscape analysis depend on CPC/IPC and citations?
    They determine the claim neighborhood and the prior-art universe; without them, any comparison is non-falsifiable.

  3. What inputs determine a validity strategy (anticipation vs obviousness)?
    Exact claim elements, their meanings in the specification, prosecution history, and the relevant prior art disclosures.

  4. How are “design-around” paths identified in a patent landscape?
    By clustering forward citations and competitor filing families around the same technical constraints.

  5. What makes enforcement risk assessment different from validity analysis?
    Enforcement depends on claim scope, claim construction likelihood, prosecution estoppel, and the patent’s litigation and licensing posture.


References

[1] United States Patent No. 9,885,024. (Bibliographic and full-text claim/specification content not provided in the prompt.)

More… ↓

⤷  Start Trial

Details for Patent 9,885,024

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Horizon Therapeutics Ireland Dac KRYSTEXXA pegloticase Injection 125293 September 14, 2010 9,885,024 2035-07-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 9,885,024

Country Patent Number Estimated Expiration
South Africa 200101814 ⤷  Start Trial
South Africa 200207206 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 0007629 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 0159078 ⤷  Start Trial
United States of America 2003166249 ⤷  Start Trial
United States of America 2005014240 ⤷  Start Trial
United States of America 2008031864 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.